Stay updated on Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial
Sign up to get notified when there's something new on the Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial page.

Latest updates to the Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial page
- Check5 days agoChange DetectedConsolidated Locations section now lists all study sites by state (CA, FL, IL, KS, MD, MT, NE, NJ, NY, TX, VA). Per-state Location headings were removed and the revision updated from v3.3.2 to v3.3.3.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe page shows Revision: v3.3.2, replacing the previous Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedThe notice about lapse in government funding and the related operating-status links have been removed from the page. As a result, users may not see warnings about information freshness or where to check current operating status.SummaryDifference0.3%

- Check55 days agoChange DetectedObserved minor formatting changes on the study page and an updated last-updated timestamp. There are no changes to core study data such as eligibility, endpoints, enrollment, or locations.SummaryDifference0.4%

- Check84 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference2%

- Check91 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Study of SV-BR-1-GM With Retifanlimab Clinical Trial page.